{"id":"prophylaxis-diphtheria-tetanus-and-pertussis","safety":{"commonSideEffects":[{"rate":"20–50","effect":"Injection site pain, redness, or swelling"},{"rate":"10–30","effect":"Fever"},{"rate":"5–15","effect":"Fatigue or malaise"},{"rate":"5–15","effect":"Myalgia"},{"rate":"5–10","effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL2108873","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated or toxoid forms of diphtheria and tetanus toxins along with pertussis antigens (acellular or whole-cell), which trigger both humoral and cell-mediated immune responses. Upon vaccination, the immune system generates protective antibodies (primarily IgG) against these pathogens and establishes immunological memory, preventing infection or severe disease if exposure occurs.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:30:24.244Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prophylaxis of diphtheria"},{"name":"Prophylaxis of tetanus"},{"name":"Prophylaxis of pertussis"}]},"trialDetails":[{"nctId":"NCT05237947","phase":"PHASE4","title":"Single-Dose HPV Vaccination for the Prevention of Cervical Cancer in Young Adult Women in Costa Rica, The PRISMA ESCUDDO Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-03-01","conditions":"Human Papillomavirus-Related Cervical Carcinoma","enrollment":5000},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT02518555","phase":"PHASE2","title":"Ibrutinib as an Immune Modulating Agent for Patients With Asymptomatic, High-risk CLL/SLL Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jennifer Woyach","startDate":"2016-01-12","conditions":"Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma","enrollment":42},{"nctId":"NCT03180034","phase":"PHASE4","title":"Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-29","conditions":"Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma","enrollment":27945},{"nctId":"NCT02868970","phase":"PHASE4","title":"Pharmacists as Immunizers to Improve Coverage and Provider/Recipient Satisfaction","status":"COMPLETED","sponsor":"Canadian Immunization Research Network","startDate":"2017-02-15","conditions":"Healthy","enrollment":2404},{"nctId":"NCT04302675","phase":"NA","title":"Adapting Motivational Interviewing for Maternal Immunizations (MI4MI)","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2020-05-27","conditions":"Maternal Immunization","enrollment":1350},{"nctId":"NCT04303494","phase":"","title":"Predictive Value of Heart Rate Variability on Cardiorespiratory Events","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2018-07-01","conditions":"Post-immunisation Apnoea and Bradycardia of Prematurity (AOP)","enrollment":292},{"nctId":"NCT00136604","phase":"PHASE3","title":"Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-22","conditions":"Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B","enrollment":617},{"nctId":"NCT00282295","phase":"PHASE4","title":"US-licensed Combined Vaccine Against Tetanus & Diphtheria, Given With US-licensed Vaccine Against Meningococcal Disease","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-01-25","conditions":"Acellular Pertussis, Tetanus, Diphtheria","enrollment":1344},{"nctId":"NCT00346073","phase":"PHASE3","title":"Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-07-13","conditions":"Acellular Pertussis, Diphtheria, Tetanus","enrollment":2337},{"nctId":"NCT00291343","phase":"PHASE3","title":"Immune Response & Safety of GSK Biologicals' Mencevax™ ACWY in Subjects Primed in the DTPW-HBV=HIB-MENAC-TT-011 Study","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02-01","conditions":"Infections, Meningococcal","enrollment":296},{"nctId":"NCT00158756","phase":"PHASE3","title":"Immune Response Post Pry Vaccination of 2 Formulations of DTPw-HBV Vaccine Given With Rotavirus Vaccine to Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-09-12","conditions":"Hepatitis B","enrollment":308},{"nctId":"NCT00317109","phase":"PHASE3","title":"Study to Asses DTPw-HBV/Hib at 15-18 Months (m) and Mencevax™ ACW at 24 to 30 m in Primed Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-04-19","conditions":"Infections, Meningococcal","enrollment":168},{"nctId":"NCT00657709","phase":"PHASE3","title":"Immunogenicity, Safety and Lot to Lot Consistency of Novartis Meningococcal B Recombinant Vaccine When Administered With Routine Infant Vaccinations to Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-03","conditions":"Serogroup B Meningococcal Meningitis","enrollment":3630},{"nctId":"NCT03107312","phase":"","title":"Bioarray for the Serological Assessment of Immunity Against Vaccine-preventable Infections","status":"UNKNOWN","sponsor":"Jena University Hospital","startDate":"2017-04-01","conditions":"Immunization; Infection","enrollment":900},{"nctId":"NCT00197275","phase":"PHASE3","title":"Lot-to-lot Consistency of Tritanrix™-HepB/Hib-MenAC & Its Non-inferiority vs Tritanrix™-HepB/Hiberix™ in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-02","conditions":"Tetanus, Hepatitis B, Haemophilus Influenzae Type b","enrollment":800},{"nctId":"NCT00263692","phase":"PHASE2","title":"Comparison of GSK Biologicals' DTaP-IPV Candidate Vaccine to DTaP and IPV Separately Administered Vaccines in Terms of Immune Response and Safety","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Diphtheria, Acellular Pertussis, Tetanus","enrollment":401},{"nctId":"NCT00263679","phase":"PHASE3","title":"Assessment of GSK Biologicals' Tdap Candidate Vaccine Administered as a Booster (6th Dose) in Terms of Immunogenicity and Safety to Children and Adolescents Previously Vaccinated With Five Doses of an Acellular Pertussis-containing Vaccine.","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2003-11","conditions":"Acellular Pertussis, Diphtheria, Tetanus","enrollment":321},{"nctId":"NCT00109330","phase":"PHASE3","title":"A Combined Tdap Vaccine Used As A Booster Compared To Licensed Td Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2002-11","conditions":"Diphtheria, Tetanus, Acellular Pertussis","enrollment":4116},{"nctId":"NCT00381615","phase":"PHASE2","title":"Prevention, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2006-09","conditions":"Healthy","enrollment":147},{"nctId":"NCT00721396","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of Meningococcal B Recombinant Vaccine Administered With or Without Routine Infant Vaccinations to Healthy Infants According to Different Immunization Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-08","conditions":"Meningococcal Infections","enrollment":1885},{"nctId":"NCT01367158","phase":"PHASE2","title":"Safety, Tolerability and Immunogenicity of a Third Dose of One of Four Different Formulations of rMenB + MenACWY Combination Vaccine in Adolescents Who Previously Received the Same Study Vaccines","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2011-07","conditions":"Meningococcal Disease, Meningococcal Meningitis","enrollment":440},{"nctId":"NCT00488683","phase":"PHASE2","title":"B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-07","conditions":"Meningococcal Disease","enrollment":216},{"nctId":"NCT00294294","phase":"PHASE4","title":"Study Evaluating Treatment of Fever in Children Who Have Been Vaccinated With Prevenar and Infanrix Hexa","status":"COMPLETED","sponsor":"Wyeth is now a wholly owned subsidiary of Pfizer","startDate":"2005-05","conditions":"Vaccines, Pneumococcal, Infant, Fever, Chemically Induced","enrollment":300},{"nctId":"NCT00674908","phase":"PHASE4","title":"Phase IV Interchangeability Study of a Liquid Pentavalent Combination Vaccine","status":"COMPLETED","sponsor":"Shantha Biotechnics Limited","startDate":"2008-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":144},{"nctId":"NCT00617812","phase":"PHASE4","title":"Safety and Immunogenicity Study of a Liquid Pentavalent Combination Vaccine","status":"COMPLETED","sponsor":"Shantha Biotechnics Limited","startDate":"2008-03","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":160},{"nctId":"NCT00877357","phase":"PHASE4","title":"Safety, Long Term Immunogenicity and Lot Consistency Study of Liquid Pentavalent Combination Vaccine","status":"UNKNOWN","sponsor":"Shantha Biotechnics Limited","startDate":"2009-01","conditions":"Diphtheria, Tetanus, Pertussis","enrollment":3000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":152,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Prophylaxis: Diphtheria, tetanus and pertussis","genericName":"Prophylaxis: Diphtheria, tetanus and pertussis","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria toxin, tetanus toxin, and pertussis antigens. Used for Prophylaxis of diphtheria, Prophylaxis of tetanus, Prophylaxis of pertussis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}